Trial explores potential of therapy in treating multiple cancer types Bayer has begun a phase 1 clinical trial for BAY3498264 ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...

Mirati Therapeutics Inc. has divulged GTPase KRAS (G12S mutant) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

DELHI, DELHI, INDIA, November 28, 2024 /EINPresswire / -- The Growth of the KRAS Inhibitors Market is expected to be mainly driven by increasing incidence, a rise in awareness and access to ...

BAY3498264 is an investigational oral selective SOS1 inhibitor with potential to treat a variety of KRAS-mutated cancers, such as non-small cell lung cancer, pancreatic cancer and colorectal cancer ...

Hanmi Pharmaceutical Co. Ltd. is developing a SOS1 inhibitor, HM-99462, and recently divulged results of initial preclinical studies. SOS1 is a guanine nucleotide exchange factor (GEF) that activates ...

Cogent Biosciences (COGT) announced the addition of a potent and selective KRAS inhibitor to its pipeline. Preclinical data from this program as well as its newly announced H1047R mutant-selective ...

Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven ...

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute ...